公开(公告)号：US20200289471A1

公开(公告)日：2020-09-17

申请号：US16861281

申请日：2020-04-29

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary, Department of Health and Human Servic ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： HENGLI TANG ,  EMILY M. LEE ,  WEI ZHENG ,  RUILI HUANG ,  MIAO XU ,  WENWEI HUANG ,  KHALIDA SHAMIM ,  GUOLI MING ,  HONGJUN SONG

IPC分类号： A61K31/4184 ,  A61K31/165 ,  A61K31/4741 ,  A61K31/352 ,  A61K31/4709 ,  A61K31/4535 ,  A61K31/517 ,  A61K31/519 ,  A61K31/427 ,  A61K31/336 ,  A61P31/14 ,  A61K31/433 ,  A61K31/245 ,  A61K31/554 ,  A61K31/422 ,  A61K31/4162 ,  A61K31/506

摘要： The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

公开(公告)号：US20220362217A1

公开(公告)日：2022-11-17

申请号：US17809339

申请日：2022-06-28

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary, Department of Health and Human Servic ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： HENGLI TANG ,  EMILY M. LEE ,  WEI ZHENG ,  RUILI HUANG ,  MIAO XU ,  WENWEI HUANG ,  KHALIDA SHAMIM ,  GUOLI MING ,  HONGJUN SONG

IPC分类号： A61K31/4184 ,  A61K31/245 ,  A61K31/433 ,  A61K31/4535 ,  A61K31/4162 ,  A61K31/517 ,  A61K31/4741 ,  A61K31/554 ,  A61K31/422 ,  A61K31/4709 ,  A61K31/336 ,  A61K31/427 ,  A61K31/506 ,  A61K31/519 ,  A61K31/352 ,  A61P31/14 ,  A61K31/165

摘要： The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

公开(公告)号：US20200164051A1

公开(公告)日：2020-05-28

申请号：US16779132

申请日：2020-01-31

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary, Department of Health and Human Servic ,  JOHNS HOPKINS UNIVERSITY

发明人： HENGLI TANG ,  EMILY M. LEE ,  YICHEN CHENG ,  YI ZHOU ,  WEI ZHENG ,  RUILI HUANG ,  MIAO XU ,  WENWEI HUANG ,  MENGHANG XIA ,  HONGJUN SONG ,  GUO-LI MING ,  ZHEXING WEN

IPC分类号： A61K38/55 ,  A61K31/609 ,  A61K45/06 ,  C07C239/08 ,  C07C239/02 ,  A61K38/43 ,  A61K31/24

摘要： The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

公开(公告)号：US20220323420A1

公开(公告)日：2022-10-13

申请号：US17809353

申请日：2022-06-28

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary , Department of Health and Human Servi ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： HENGLI TANG ,  EMILY M. LEE ,  WEI ZHENG ,  RUILI HUANG ,  MIAO XU ,  WENWEI HUANG ,  KHALIDA SHAMIM ,  GUOLI MING ,  HONGJUN SONG

IPC分类号： A61K31/4184 ,  A61K31/245 ,  A61K31/433 ,  A61K31/4535 ,  A61K31/4162 ,  A61K31/517 ,  A61K31/4741 ,  A61K31/554 ,  A61K31/422 ,  A61K31/4709 ,  A61K31/336 ,  A61K31/427 ,  A61K31/506 ,  A61K31/519 ,  A61K31/352 ,  A61P31/14 ,  A61K31/165

摘要： The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

公开(公告)号：US20220323419A1

公开(公告)日：2022-10-13

申请号：US17809327

申请日：2022-06-28

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary, Department of Health and Human ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： HENGLI TANG ,  EMILY M. LEE ,  WEI ZHENG ,  RUILI HUANG ,  MIAO XU ,  WENWEI HUANG ,  KHALIDA SHAMIM ,  GUOLI MING ,  HONGJUN SONG

IPC分类号： A61K31/4184 ,  A61K31/245 ,  A61K31/433 ,  A61K31/4535 ,  A61K31/4162 ,  A61K31/517 ,  A61K31/4741 ,  A61K31/554 ,  A61K31/422 ,  A61K31/4709 ,  A61K31/336 ,  A61K31/427 ,  A61K31/506 ,  A61K31/519 ,  A61K31/352 ,  A61P31/14 ,  A61K31/165

摘要： The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

公开(公告)号：US20180015153A1

公开(公告)日：2018-01-18

申请号：US15650568

申请日：2017-07-14

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary, Department of Health and Human Serv ,  JOHNS HOPKINS UNIVERSITY

发明人： HENGLI TANG ,  EMILY M. LEE ,  YICHEN CHENG ,  YI ZHOU ,  WEI ZHENG ,  RUILI HUANG ,  MIAO XU ,  WENWEI HUANG ,  MENGHANG XIA ,  HONGJUN SONG ,  GUO-LI MING ,  ZHEXING WEN

IPC分类号： A61K38/55 ,  A61K31/24 ,  A61K38/43 ,  C07C239/08 ,  C07C239/02 ,  A61K38/00

CPC分类号： A61K38/55 ,  A61K31/24 ,  A61K31/609 ,  A61K38/00 ,  A61K38/43 ,  A61K45/06 ,  C07C239/02 ,  C07C239/08 ,  Y02A50/391 ,  A61K2300/00

摘要： The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.